Literature DB >> 33512637

Concentration-QTc analysis for single arm studies.

Yasushi Orihashi1, Shoichi Ohwada2, Yuji Kumagai3.   

Abstract

Concentration-QTc (C-QTc) modeling is being increasingly used in phase 1 studies. For studies without a placebo arm (single arm studies), the scientific whitepaper by Garnett et al. ( https://doi.org/10.1007/s10928-017-9558-5 ) states that time-matched baseline adjustments may minimize the effect of diurnal variation in QTc intervals, and categorical time effects are not needed in the model. However, how diurnal variations can be accounted for when only pre-dose baselines are available is unclear. This research investigates whether including categorical time effects in the model can adjust diurnal variation in single arm studies with pre-dose baselines, where QTc prolongation is evaluated at a concentration of interest based on ΔQTc at 24 h and ΔΔQTc (a model-derived difference in ΔQTc from concentration zero). To understand the operating characteristics for the models with and without categorical time effects, simulations were conducted under various scenarios considering oncology early phase studies. When the C-QTc relationship is linear, models without categorical time effects provided biased estimates for model parameters and inflated or decreased false negative rates (FNRs) depending on the pattern of diurnal variations in QTc intervals, whereas models with categorical time effects caused no biases and controlled the FNRs. For non-linear C-QTc relationships, ΔΔQTc estimations made using the model with categorical time effects were not robust. Thus, for single arm studies where only pre-dose baselines are available, we recommend collecting QTc measurements at 24 h and estimating ΔQTc at a concentration of interest at 24 h using the C-QTc model with categorical time effects.

Entities:  

Keywords:  Concentration-QTc model; Diurnal variation; ICH E14; Mixed effects model; Single arm study

Mesh:

Substances:

Year:  2021        PMID: 33512637     DOI: 10.1007/s10928-021-09737-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  15 in total

1.  Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.

Authors:  Zhaoling Meng; Robert Kringle; Xun Chen; Peng-Liang Zhao
Journal:  J Biopharm Stat       Date:  2010-05       Impact factor: 1.051

2.  Sample size calculations in thorough QT studies.

Authors:  Lu Zhang; Alex Dmitrienko; George Luta
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

3.  Enabling robust assessment of QTc prolongation in early phase clinical trials.

Authors:  Devan V Mehrotra; Li Fan; Fang Liu; Kuenhi Tsai
Journal:  Pharm Stat       Date:  2017-04-03       Impact factor: 1.894

4.  Circadian Variation and Baseline Definition in Parallel-Group Thorough QT Studies.

Authors:  David Hoffman
Journal:  Ther Innov Regul Sci       Date:  2014-03       Impact factor: 1.778

Review 5.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

6.  Population Pharmacokinetic-Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects.

Authors:  Hyang-Ki Choi; Jin Ah Jung; Tomoe Fujita; Hideki Amano; Jong-Lyul Ghim; Dong-Hwan Lee; Kenichi Tabata; Il-Dae Song; Mika Maeda; Yuji Kumagai; Boaz Mendzelevski; Jae-Gook Shin
Journal:  Clin Ther       Date:  2016-12       Impact factor: 3.393

7.  Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.

Authors:  Elodie Valade; Anne-Gaëlle Dosne; Hong Xie; Robert Kleiman; Lilian Y Li; Juan José Perez-Ruixo; Daniele Ouellet
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-06       Impact factor: 3.333

8.  An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.

Authors:  Bodine P S I Belderbos; Ronald de Wit; Caly Chien; Anna Mitselos; Peter Hellemans; James Jiao; Margaret K Yu; Gerhardt Attard; Iurie Bulat; W Jeffrey Edenfield; Fred Saad
Journal:  Cancer Chemother Pharmacol       Date:  2018-07-05       Impact factor: 3.333

9.  Evaluation of the potential for QTc prolongation with avelumab.

Authors:  Yulia Vugmeyster; Gülseren Güzel; Meliessa Hennessy; Anja H Loos; Haiqing Dai
Journal:  Cancer Chemother Pharmacol       Date:  2019-09-03       Impact factor: 3.333

10.  Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Authors:  Boaz Mendzelevski; Georg Ferber; Filip Janku; Bob T Li; Ryan J Sullivan; Dean Welsch; Wei Chi; Jeanne Jackson; Onglee Weng; Philip T Sager
Journal:  Cancer Chemother Pharmacol       Date:  2018-03-30       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.